FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145471187> ?p ?o ?g. }

• W2145471187 endingPage "698" @default.
• W2145471187 startingPage "692" @default.
• W2145471187 abstract "To explore further topical antiviral therapy for recurrent genital herpes, 188 culture-proven patients were randomized to receive treatment with topical interferon-a in high-dose (106 IU/g with 1% nonoxynol-9 in 3.5% methylcellulose) or low-dose (103 IU/g with 0.1% nonoxynol-9 in 3.5% methylcellulose) treatments or placebo (3.5% methylcellulose, alone), applied three times daily for 5 days. Of these, 105 experienced prodromal symptoms within the study period and applied the medication, of whom 99 could be evaluated for efficacy. Patients were followed with daily clinical assessments and cultures until reepithelialization. The median time to negative virus culture in high-dose recipients was 2.5 days compared with 3.9 days for placebo recipients (P = .023), and a significant dose response was observed (P = .016). Antiviral effects were more prominent in men than women. High-dose recipients also had reduced median duration of symptoms to 2.7 days from 3.7 days for placebo recipients (P = .03), with a significant dose-response relationship (P = .047). Effects on duration of symptoms were more prominent in women. Times to complete reepithelialization in those who applied the drug during the prodromal phase were 5.8 days for high-dose recipients compared with 6.5 days for placebo recipients (P = .053). A multivariate ranked linear model analysis of four efficacy variables (crusting, healing, virus shedding, symptom duration) also favored the high-dose gel (P = .015). High-dose topical interferon-α preparation is effective for patients with recurrent genital herpes. Applied early in the course of a recurrent episode, this treatment is safe and may provide a topical alternative to other types of therapy in the future." @default.
• W2145471187 created "2016-06-24" @default.
• W2145471187 creator A5017243047 @default.
• W2145471187 creator A5027140017 @default.
• W2145471187 creator A5037989417 @default.
• W2145471187 creator A5040831961 @default.
• W2145471187 creator A5066815217 @default.
• W2145471187 creator A5071955362 @default.
• W2145471187 creator A5089977425 @default.
• W2145471187 date "1990-04-01" @default.
• W2145471187 modified "2023-09-26" @default.
• W2145471187 title "Randomized, Double-Blind, Placebo-Controlled, Patient-Initiated Study of Topical High- and Low-Dose Interferon- with Nonoxynol-9 in the Treatment of Recurrent Genital Herpes" @default.
• W2145471187 cites W1494628690 @default.
• W2145471187 cites W1529972356 @default.
• W2145471187 cites W1600491697 @default.
• W2145471187 cites W1897543726 @default.
• W2145471187 cites W1964522214 @default.
• W2145471187 cites W1971139739 @default.
• W2145471187 cites W1978565738 @default.
• W2145471187 cites W1979300931 @default.
• W2145471187 cites W1981081771 @default.
• W2145471187 cites W1983098285 @default.
• W2145471187 cites W1987167147 @default.
• W2145471187 cites W1991572243 @default.
• W2145471187 cites W1997690359 @default.
• W2145471187 cites W2001783515 @default.
• W2145471187 cites W2004794807 @default.
• W2145471187 cites W2006495407 @default.
• W2145471187 cites W2012184171 @default.
• W2145471187 cites W2016348314 @default.
• W2145471187 cites W2020336513 @default.
• W2145471187 cites W2022053588 @default.
• W2145471187 cites W2026801367 @default.
• W2145471187 cites W2032526219 @default.
• W2145471187 cites W2052460032 @default.
• W2145471187 cites W2062683462 @default.
• W2145471187 cites W2067118642 @default.
• W2145471187 cites W2088152779 @default.
• W2145471187 cites W2089193554 @default.
• W2145471187 cites W2089277425 @default.
• W2145471187 cites W2099618133 @default.
• W2145471187 cites W2130145455 @default.
• W2145471187 cites W2144529000 @default.
• W2145471187 cites W2145391048 @default.
• W2145471187 cites W2148791750 @default.
• W2145471187 cites W2149718597 @default.
• W2145471187 cites W2324811851 @default.
• W2145471187 cites W2325343629 @default.
• W2145471187 cites W2325525067 @default.
• W2145471187 cites W2331111727 @default.
• W2145471187 cites W2338176289 @default.
• W2145471187 cites W2338896046 @default.
• W2145471187 cites W2408810424 @default.
• W2145471187 cites W2796700885 @default.
• W2145471187 cites W92989534 @default.
• W2145471187 cites W1952070618 @default.
• W2145471187 doi "https://doi.org/10.1093/infdis/161.4.692" @default.
• W2145471187 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2156945" @default.
• W2145471187 hasPublicationYear "1990" @default.
• W2145471187 type Work @default.
• W2145471187 sameAs 2145471187 @default.
• W2145471187 citedByCount "23" @default.
• W2145471187 countsByYear W21454711872015 @default.
• W2145471187 countsByYear W21454711872021 @default.
• W2145471187 crossrefType "journal-article" @default.
• W2145471187 hasAuthorship W2145471187A5017243047 @default.
• W2145471187 hasAuthorship W2145471187A5027140017 @default.
• W2145471187 hasAuthorship W2145471187A5037989417 @default.
• W2145471187 hasAuthorship W2145471187A5040831961 @default.
• W2145471187 hasAuthorship W2145471187A5066815217 @default.
• W2145471187 hasAuthorship W2145471187A5071955362 @default.
• W2145471187 hasAuthorship W2145471187A5089977425 @default.
• W2145471187 hasConcept C126322002 @default.
• W2145471187 hasConcept C141071460 @default.
• W2145471187 hasConcept C142724271 @default.
• W2145471187 hasConcept C168563851 @default.
• W2145471187 hasConcept C203014093 @default.
• W2145471187 hasConcept C204787440 @default.
• W2145471187 hasConcept C2522874641 @default.
• W2145471187 hasConcept C27081682 @default.
• W2145471187 hasConcept C2778498788 @default.
• W2145471187 hasConcept C2781196997 @default.
• W2145471187 hasConcept C2909813250 @default.
• W2145471187 hasConcept C71924100 @default.
• W2145471187 hasConcept C90924648 @default.
• W2145471187 hasConceptScore W2145471187C126322002 @default.
• W2145471187 hasConceptScore W2145471187C141071460 @default.
• W2145471187 hasConceptScore W2145471187C142724271 @default.
• W2145471187 hasConceptScore W2145471187C168563851 @default.
• W2145471187 hasConceptScore W2145471187C203014093 @default.
• W2145471187 hasConceptScore W2145471187C204787440 @default.
• W2145471187 hasConceptScore W2145471187C2522874641 @default.
• W2145471187 hasConceptScore W2145471187C27081682 @default.
• W2145471187 hasConceptScore W2145471187C2778498788 @default.
• W2145471187 hasConceptScore W2145471187C2781196997 @default.
• W2145471187 hasConceptScore W2145471187C2909813250 @default.
• W2145471187 hasConceptScore W2145471187C71924100 @default.
• W2145471187 hasConceptScore W2145471187C90924648 @default.

• next